CClinicalTrials.gg
CompletedNCT05312723Updated Apr 14, 2022

Sleep Disturbance in Chronic Rhinitis

An observational study in Sleep Disturbance, sponsored by Indonesia University. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-04-14.

Sponsored by Indonesia University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
22
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the characteristic of sleep disturbance in allergic and non-allergic rhinitis in Dr. Cipto Mangunkusumo Hospital, Jakarta. A cross sectional analytic descriptive study with consecutive sampling was performed. A total of 22 chronic rhinitis patients, consisted of 11 allergic and 11 non-allergic rhinitis were evaluated of their sleep disturbance's characteristics.

Read the detailed description

At first, all recruited subjects were evaluated for total nasal symptom scores (TNSS) and nasal obstruction symptoms evaluation scores (NOSE). Sleep disorder was assessed using Epworth Sleepiness Scale (ESS), Pittsburg Sleep Quality Index (PSQI) questionnaires, and polysomnography (PSG). Both the allergic and non-allergic rhinitis groups will be compared in terms of their sleep disturbance characteristics (from comparing ESS, PSQI, and PSG results).

02

Conditions studied

  • Sleep Disturbance

Keywords

  • allergic
  • nasal congestion
  • daytime sleepiness
  • polysomnography
03

In context

Rhinitis

1,105 studies on the registry are indexed under Rhinitis; 65 are open to participants now.

This study's enrollment of 22 is below the median of 141 across 172 observational studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Indonesia University is the lead sponsor of 448 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Allergic and non-allergic rhinitis patients

Inclusion criteria

  • All male and female between 18-60 years old with chronic rhinitis symptoms and sleep disorder
  • Did not receive intranasal steroid within the last one month
  • Have psychiatric disorder

Exclusion criteria

Exclusion Criteria:

  • Polyp
  • Nasal or sinonasal tumor
  • Septum deviation
  • Chronic rhinosinusitis
  • Adenoid hypertrophy
  • Tonsil hypertrophy
  • Macroglossia
  • Oropharyngeal tumor
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
22 participants (actual)
Patient registry
No

Groups and cohorts

  • Rhinitis allergy

    Patients with rhinitis symptoms and positive skin pric test to one or more allergens.

  • Non-rhinitis allergy

    Patients with rhinitis symptoms and negative skin pric test to one or more allergens.

06

What researchers measure

Primary outcomes

  1. Mean value of TNSS based on VAS symptoms

    Clinical symptoms was evaluated by visual analogue scale (VAS) based on total nasal symptoms score (TNSS). Total nasal symptoms score are based on four symptoms, which are rhinorrea, sneezing, itchy nose, and nose obstruction. Each symptom will be given a score between 1 (most mild symptom) until 5 (most severe symptom). The minum score for VAS based on TNSS is 4 (most mild symptom) and the maximum score is 40 (most severe symptom). VAS score less than five indicates a controlled rhinitis symptoms, while ≥ 5 indicates that symptoms are not controlled.

    Time frame: Evaluation is done at Day 1(cross-sectional)

  2. Nasal obstruction symtpms evaluation (NOSE) score

    Nasal obstruction symptoms was evaluated by NOSE score. It evaluates 5 items that indicates nasal obstruction symptoms that was experienced in the past 1 month. Each item has a score range from 0 to 20. It has a minimum score of 0 and a maximum score of 100. Score 5-25 indicates mild nasal obstruction, score 30-50 indicates moderate nasal obstruction, score 55-75 indicates severe nasal obstruction, and score \> 80 indicates extreme nasal obstruction.

    Time frame: Evaluation is done at Day 1 (cross-sectional)

  3. Sleep quality from Epworth sleepiness scale (ESS)

    Sleep quality assessed by Epworth sleepiness scale. ESS is a self-administered questionnaire consisted of 8 questions. It assessed the chances of falling asleep while engaged in different activities. Each item scored 0-3, with a minimum score of 0 (low normal daytime sleepiness) and a maximum score of 24 (severe daytime sleepiness). In this study, the cut off is score 5-9 indicates mild daytime sleepiness and score \> 10 indicates severe daytime sleepiness.

    Time frame: Evaluation is done at Day 1 (cross-sectional)

  4. Sleep quality from Pittsburg Sleep Quality Index (PSQI)

    Sleep quality assessed by Pittsburg Sleep Quality Index. PSQI consisted of 10 questions. These 10 questions were divided to 7 components, including subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction. Each component score range from 0-23. Total score can range from 0 to 21. Score \< 5 indicates good sleep quality and \> 5 indicates poor sleep quality

    Time frame: Evaluation is done at Day 1 (cross-sectional)

  5. Objective sleep measurement using polysomnography (PSG)

    Sleep parameters were objectively measured using polysomnography (PSG). Sleep architecture was assessed using non-rapid eye movement (NREM)/ rapid eye movement (REM) and respiratory analysis was assessed using respiratory disturbance index - rapid eye movement (RDI-REM) and respiratory effort related arousals (RERA). All the parameters will be presented as numeric data.

    Time frame: Evaluation is done at Day 1 (cross-sectional)

07

Study locations

1 site
  • RSUPN Dr. Cipto Mangunkusumo
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05312723
Lead sponsor
Indonesia University
Responsible party
Nina Irawati (Head of Allergy Immunology Division, Otorhinolaryngology Head and Neck Surgery Department, Indonesia University) — Principal investigator
First posted
Apr 5, 2022
Start date
Mar 15, 2020
Primary completion
Aug 15, 2020
Completion
Aug 15, 2020
Last update
Apr 14, 2022

Study contacts

Nina Irawati
principal investigator · Indonesia University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion